|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Scully C and Bagan J: Oral squamous cell
carcinoma overview. Oral Oncol. 45:301–308. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saraswathi TR, Kavitha B and Vijayashree
Priyadharsini J: Gene therapy for oral squamous cell carcinoma: an
overview. Indian J Dent Res. 18:120–123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shurin MR, Umansky V, Malyguine A, et al:
Cellular and molecular pathways in the tumor immunoenvironment: 3rd
Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, 22–25
April 2013, Krakow, Poland. Cancer Immunol Immunother. 63:73–80.
2014.PubMed/NCBI
|
|
5
|
Sihver W, Pietzsch J, Krause M, Baumann M,
Steinbach J and Pietzsch HJ: Radiolabeled cetuximab conjugates for
EGFR targeted cancer diagnostics and therapy. Pharmaceuticals.
7:311–338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Bono JS and Rowinsky EK: The ErbB
receptor family: a therapeutic target for cancer. Trends Mol Med.
8:S19–S26. 2002.PubMed/NCBI
|
|
8
|
Carpenter G: Receptors for epidermal
growth factor and other polypeptide mitogens. Annu Rev Biochem.
56:881–914. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salomon DS, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wells A: EGF receptor. Int J Biochem Cell
Biol. 31:637–643. 1999. View Article : Google Scholar
|
|
11
|
Yarden Y: The EGFR family and its ligands
in human cancer: signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37:S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wikstrand CJ, Hale LP, Batra SK, et al:
Monoclonal antibodies against EGFRvIII are tumor specific and react
with breast and lung carcinomas and malignant gliomas. Cancer Res.
55:3140–3148. 1995.PubMed/NCBI
|
|
13
|
Herbst RS and Langer CJ: Epidermal growth
factor receptors as a target for cancer treatment: the emerging
role of IMC-C225 in the treatment of lung and head and neck
cancers. Semin Oncol. 29:27–36. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sridhar SS, Seymour L and Shepherd FA:
Inhibitors of epidermal-growth-factor receptors: a review of
clinical research with a focus on non-small-cell lung cancer.
Lancet Oncol. 4:397–406. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Humblet Y: Cetuximab: an IgG(1) monoclonal
antibody for the treatment of epidermal growth factor
receptor-expressing tumours. Expert Opin Pharmacother. 5:1621–1633.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harding J and Burtness B: Cetuximab: an
epidermal growth factor receptor chemeric human-murine monoclonal
antibody. Drugs Today. 41:107–127. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SJ, Kim MJ, Kim YK, Kim SM, Park JY
and Myoung H: Combined cetuximab and genistein treatment shows
additive anti-cancer effect on oral squamous cell carcinoma. Cancer
Lett. 292:54–63. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tol J, Koopman M, Cats A, et al:
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal
cancer. N Engl J Med. 360:563–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hattar K, Savai R, Subtil FS, et al:
Endotoxin induces proliferation of NSCLC in vitro and in vivo: role
of COX-2 and EGFR activation. Cancer Immunol Immunother.
62:309–320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese
JL and Xie K: Celecoxib inhibits vascular endothelial growth factor
expression in and reduces angiogenesis and metastasis of human
pancreatic cancer via suppression of Sp1 transcription factor
activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar
|
|
21
|
Jeon YW and Suh YJ: Synergistic apoptotic
effect of celecoxib and luteolin on breast cancer cells. Oncol Rep.
29:819–825. 2013.PubMed/NCBI
|
|
22
|
Kao J, Sikora AT and Fu S: Dual EGFR and
COX-2 inhibition as a novel approach to targeting head and neck
squamous cell carcinoma. Curr Cancer Drug Targets. 9:931–937. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang H, Li Z and Wang K: Combining
sorafenib with celecoxib synergistically inhibits tumor growth of
non-small cell lung cancer cells in vitro and in
vivo. Oncol Rep. 31:1954–1960. 2014.PubMed/NCBI
|
|
24
|
Ratti M and Tomasello G: Emerging
combination therapies to overcome resistance in EGFR-driven tumors.
Anticancer Drugs. 25:127–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pal SK and Pegram M: Epidermal growth
factor receptor and signal transduction: potential targets for
anti-cancer therapy. Anticancer Drugs. 16:483–494. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park SJ, Kim MJ, Kim YK, Kim SM, Park JY
and Myoung H: Combined cetuximab and genistein treatment shows
additive anti-cancer effect on oral squamous cell carcinoma. Cancer
Lett. 292:54–63. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maseki S, Ijichi K, Nakanishi H, Hasegawa
Y, Ogawa T and Murakami S: Efficacy of gemcitabine and cetuximab
combination treatment in head and neck squamous cell carcinoma. Mol
Clin Oncol. 1:918–924. 2013.PubMed/NCBI
|
|
28
|
Kinoshita T, Takahashi Y, Sakashita T,
Inoue H, Tanabe T and Yoshimoto T: Growth stimulation and induction
of epidermal growth factor receptor by overexpression of
cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim
Biophys Acta. 1438:120–130. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsujii M, Kawano S and DuBois RN:
Cyclooxygenase-2 expression in human colon cancer cells increases
metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sheng H, Shao J, Dixon DA, Williams CS,
Prescott SM, DuBois RN and Beauchamp RD: Transforming growth factor
beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in
intestinal epithelial cells via stabilization of mRNA. J Biol Chem.
275:6628–6635. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsujii M, Kawano S, Tsuji S, Sawaoka H,
Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced
by colon cancer cells. Cell. 93:705–716. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xia H, Ye J, Bai H and Wang C: Effects of
cetuximab combined with celecoxib on apoptosis and KDR and AQP1
expression in lung cancer. Zhongguo Fei Ai Za Zhi. 16:625–631.
2013.(In Chinese).
|
|
33
|
Jalili A, Pinc A, Pieczkowski F, Karlhofer
FM, Stingl G and Wagner SN: Combination of an EGFR blocker and a
COX-2 inhibitor for the treatment of advanced cutaneous squamous
cell carcinoma. J Dtsch Dermatol Ges. 6:1066–1069. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ullah MF: Cancer multidrug resistance
(MDR): a major impediment to effective chemotherapy. Asian Pac J
Cancer Prev. 9:1–6. 2008.PubMed/NCBI
|
|
35
|
Irie T, Tsujii M, Tsuji S, et al:
Synergistic antitumor effects of celecoxib with 5-fluorouracil
depend on IFN-gamma. Int J Cancer. 121:878–883. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morisaki T, Umebayashi M, Kiyota A, et al:
Combining celecoxib with sorafenib synergistically inhibits
hepatocellular carcinoma cells in vitro. Anticancer Res.
33:1387–1395. 2013.PubMed/NCBI
|
|
37
|
Jeon YW and Suh YJ: Synergistic apoptotic
effect of celecoxib and luteolin on breast cancer cells. Oncol Rep.
29:819–825. 2013.PubMed/NCBI
|
